Quince Therapeutics, Inc. · NASDAQ:QNCX
Quince Therapeutics — IRulya Therapeutics — Investor Presentation (October 2026)
35 slides from Quince Therapeutics's investor presentation, Oct 19, 2026
Slide 1: Corporate Presentation October 2026
CORPORATE PRESENTATION OCTOBER 2026 Exhibit 99.1
Slide 2: Disclaimers
DISCLAIMERS The information in this Presentation has been prepared by IRulya Therapeutics Inc. (formerly Quince Therapeutics, Inc., “IRulya”, and the “company”) and contains information pertaining to the business and operations of the company. The information contained in this Presentation: (a) is p
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Rare disease focused, clinical-staged biotechnology company developing a novel, once-daily, inhaled, disease modifying rapamycin formulation (LAM-001) across multiple Phase 2 programs: PH-ILD (~200K US/EU)1 –Current therapies are limited to vasodilation, not disease modifying2.
Slide 4: IRulya Pipeline and Anticipated Milestones
LAM-001 2026 2027 2028 ESTIMATED US/EU MARKET ANTICIPATED DATA READOUTS Pulmonary Hypertension-Interstitial Lung Disease (PH-ILD) ~200k 1Q-28 Bronchiolitis Obliterans Syndrome (BOS) ~30k 1Q-27 Sarcoidosis Associated PH (SAPH) ~60k 4Q-28 IRULYA PIPELINE AND ANTICIPATED MILESTONES Anticipated Data Rea
Slide 5: Limitations of Oral Rapamycin
* Systemic bioavailability of 14 – 18% due to poor aqueous solubility, high molecular weight, extensive first‑pass metabolism, variable gastrointestinal conditions, food effects, and P‑glycoprotein-mediated efflux Sirolimus (Rapamycin) prescribing information, NIH NLM; Revised 5/2026 LIMITATIONS OF
Slide 6: Solution: LAM-001 Designed for Improved Pulmonary Delivery of Rapamycin
Based on non-clinical and clinical studies conducted by the Company, Sirolimus (Rapamycin) prescribing information. NIH NLM; Revised 5/2026 No head-to-head clinical trials have been conducted evaluating LAM-001 and Rapamycin. Differences exist between study or trial designs and participant character
Slide 7: LAM-001: Inhaled Rapamycin Advantages Over Oral
ILD = interstitial lung disease Based on non-clinical and clinical studies conducted by the Company No head-to-head clinical trials have been conducted evaluating LAM-001 and Rapamycin. Differences exist between study or trial designs and participant characteristics, and caution should be exercised
Slide 8: LAM-001: Group 3 Pulmonary Hypertension (PH-ILD)
LAM-001: GROUP 3 PULMONARY HYPERTENSION (PH-ILD)
Slide 9: Pulmonary Hypertension (PH-ILD)
PULMONARY HYPERTENSION (PH-ILD) DISEASE: Rare, progressive disorder characterized by smooth muscle cell proliferation and endothelial cell dysfunction, leading to thickening and narrowing of the pulmonary blood vessels Group 3 Pulmonary Hypertension due to underlying interstitial lung disease (ILD)
Slide 10: Rapamycin Targets PH Pathology
RAPAMYCIN TARGETS PH PATHOLOGY PH SMOOTH MUSCLE CELLS (HYPOXIA) Rapamycin FKBP12 Activated mTOR Inhibited mTOR ↑ mTOR signaling ↑ Proliferation ↓ mTOR signaling ↓ Proliferation Hypoxia Hypoxia +Rapamycin Krymskaya, et. al., FASEB (2011) Growth Factor R Hassoun NEJM 2021 LAM-001 has been shown to rev
Slide 11: Rapamycin Reverses PASMC Proliferation
RAPAMYCIN REVERSES PASMC PROLIFERATION2 RAPAMYCIN INHIBITS MTOR AND REVERSES PULMONARY ARTERIAL SMOOTH MUSCLE CELL (PASMC) PROLIFERATION1,2 2 Based on Houssaini, Am J Resp Cell Mol Bio 2013 PASMC = Pulmonary Artery Smooth Muscle Cell, MCT = monocrotaline rat model MCT 3 wk Ve + Rapa 3 wk Control 1 B
Slide 12: Competitive Landscape: PH-ILD Products and Product Candidates
Tyvaso nebulized or dry powder administrations PR = Preregistration. Commercial launch anticipated 2027. +++ = Higher activity | ++ = Medium activity | + = Lower activity COMPETITIVE LANDSCAPE PH-ILD PRODUCTS AND PRODUCT CANDIDATES Company Once-daily dosing Vasodilation MOA Antiproliferative MOA Ant
Slide 13: Phase 2a Trial of LAM-001 in Group 1 PAH and Group 3 PH
1iCPET is a diagnostic procedure in which patients undergo pulmonary and radial artery catheterization in conjunction with a bicycle exercise test to directly measure cardiac and pulmonary function during exercise. Bradley A. Maron, Barbara A. Cockrill, Aaron B. Waxman, David M. Systrom “Invasive Ca
Slide 14: Phase 2a Baseline Characteristics
1 IPF = Interstitial Pulmonary Fibrosis, NSIP = Non-specific Interstitial Pneumonia, SSc-ILD = Systemic Sclerosis ILD, PS = Pulmonary Sarcoidosis 2 Inhaled, oral or SubQ Data on file PHASE 2a BASELINE CHARACTERISTICS PAH PH-ILD Completers All Enrolled N per group 5 5 6 10 Female 4 2 2 6 Male 1 3 4 4
Slide 15: Phase 2a 24 Week Data Summary
Consistent, clinically relevant improvement from baseline observed across multiple endpoints In addition to SOC therapy in heavily pre-treated population Data support potential benefit across exercise capacity, pulmonary hemodynamics, cardiac stress and lung function 6MWD = 6 Minute Walk Distance, V
Slide 16: Phase 2a Functional Class Endpoint
Data on file PHASE 2a FUNCTIONAL CLASS ENDPOINT All ten patients FC III at baseline Six of ten improved to FC II by week twelve Two patients improved to FC I Baseline Wk1 Wk4 Wk12 Wk16 Wk24 Mo 12 1 2 3 Functional Class Improvement 100% of completers improved to FC II by Week 24 WHO Functional Class
Slide 17: Safety Summary Through 24 Weeks
AEs = Adverse Events, SAEs = Serious Adverse Event Data on file SAFETY SUMMARY THROUGH 24-WEEKS DRUG RELATED AEs Grade 1 Productive Cough (n = 1) - Resolving Grade 2 Cough (n = 1) - Not Resolved Grade 1 Gingivitis (n = 1) - Resolving NO DOSE INTERRUPTIONS DUE TO AEs NO DISCONTINUATIONS DUE TO DRUG N
Slide 18: Phase 2a Efficacy and Safety Summary
1Compared to +31.1m placebo adj. improvement in the Tyvaso INCREASE Phase 3 study: Waxman 2021 DOI: 10.1056/NEJMoa2008470 No head-to-head clinical trials have been conducted evaluating LAM-001 and Tyvaso. Differences exist between study or trial designs and participant characteristics, and caution s
Slide 19: Phase 2b Trial of LAM-001 in PH-ILD
Clinical Worsening defined as the occurrence of one of the following: 1) Death, 2) Lung or heart lung transplantation, 3) Hospitalization related to worsening respiratory status/respiratory decompensation (>24 hrs), 4) Addition of or increase in dose of greater than 10% of PH-specific therapy, 5) Wo
Slide 20: LAM-001: Bronchiolitis Obliterans (BOS)
LAM-001: BRONCHIOLITIS OBLITERANS (BOS)
Slide 21: Bronchiolitis Obliterans (BOS)
1 Ehrsam 2021 doi.org/10.1016/j.healun.2021.01.887 2 Estimated population at projected launch, US HRSA Data, Kulkarni 2018:doi: 10.1016/j.healun.2018.09.016 and Company estimates 3 Adapted from researchoutreach.org BRONCHIOLITIS OBLITERANS (BOS) BOS = Bronchiolitis Obliterans Syndrome3 Estimated Add
Slide 22: BOS Major Unmet Need
BOS MAJOR UNMET NEED 11% BOS free survival at 10 yrs2 Median survival (or re-transplantation) post development of BOS post lung transplantation4 Median survival post lung transplantation1 BOS is the leading cause of death post lung transplantation3 6.2 YEARS #1 2.5 YEARS 1ISHLT Factsheet: https://ww
Slide 23: FEV1 Is Key Measure of BOS Progression and Survival
72% FEV1 IS KEY MEASURE OF BOS PROGRESSION AND SURVIVAL *Baseline = best post-transplant FEV1 Meyer 2014: DOI: 10.1183/09031936.00107514 Kneidinger 2022 doi: 10.3389/fmed.2022.897581 PROGRESSION TO ADVANCED BOS IS MEASURED BY FEV1 DECLINE* 1% decrease in FEV1 is associated with a 3.4% increase in Mo
Slide 24: Rapamycin Stabilizes Pulmonary Function in Patients with BOS
Oral rapamycin administered to patients with progressive BOS post lung transplant who had not responded to other treatments Mean FEV1 Values Before and After Rapamycin 1Based on Hernandez, et. al. Transplantation Proceedings, 2005. DOI: 10.1016/j.transproceed.2005.09.191 RAPAMYCIN STABILIZES PULMONA
Slide 25: Phase 2 Trial of LAM-001 in BOS
DESIGN Randomized 1:1, Double Blind, Placebo controlled, 25 mo open-label extension, Investigator-initiated trial INCLUSION >18 yo; Newly diagnosed BOS (FEV1 51-85% of baseline, ≤ 12 mo from BOS diagnosis); ≥ 12 mo post Double lung transplant PRIMARY ENDPOINTS % Δ in FEV1 @ 48 wks (or at termination
Slide 26: LAM-001: Sarcoidosis Associated Pulmonary Hypertension (SAPH)
LAM-001: SARCOIDOSIS ASSOCIATED PULMONARY HYPERTENSION (SAPH)
Slide 27: Sarcoidosis Associated Pulmonary Hypertension (SAPH)
SARCOIDOSIS ASSOCIATED PULMONARY HYPERTENSION (SAPH) Pulmonary Sarcoidosis DISEASE: Sarcoidosis is a disease characterized by the growth of abnormal masses of cells called granulomas Lungs are affected in 90% of cases (pulmonary sarcoidosis) SAPH: a severe complication that occurs in 15% of cases1 5
Slide 28: Clinical Case Study (Rapamycin): Pulmonary Sarcoidosis
Patient PET scans before and after JAKi and Rapamycin (sirolimus) treatment Clinical Case Study (Rapamycin): Pulmonary Sarcoidosis Patient with severe pulmonary sarcoidosis failed to respond to prednisone, azathioprine, methotrexate, hydroxychloroquine, infliximab and adalimumab JAK inhibitor (JAKi)
Slide 29: mTOR Inhibition Demonstrates Activity in Cutaneous Sarcoidosis
mTOR Inhibition Demonstrates Activity in Cutaneous Sarcoidosis N=3 N=7 N=3 N=7 Cutaneous Sarcoidosis Activity and Morphology Index mTOR activity in dermal skin cells Skin immune and non-immune cells upon systemic mTOR inhibition Subjects with Cutaneous Sarcoidosis treated with Oral Rapamycin for 4 m
Slide 30: Phase 2 Trial of LAM-001 in SAPH
PHASE 2 TRIAL OF LAM-001 IN SAPH1 60 patients 100 µg LAM-001 qd (20 pts) 200 µg LAM-001 qd (20 pts) Placebo (20 pts) LAM-001 qd (60 pts) Screening Week 0 Week 24 Week 48 BLINDED TREATMENT PHASE OPEN LABEL EXTENSION 1 Proposed study design 2 All secondary endpoints at 24 wks unless otherwise specifie
Slide 31: IP, Financial, & Milestones
IP, FINANCIAL, & MILESTONES
Slide 32: Broad IP Strategy Supporting LAM-001 Exclusivity
* Australia, Canada, Europe, Hong Kong, Israel, Japan, Mexico, New Zealand and South Korea. BROAD IP STRATEGY SUPPORTING LAM-001 EXCLUSIVITY FDA ORANGE BOOK AFFORDS PROTECTION FOR 3 TYPES OF PATENTS METHOD CLAIMS Method of Treatment (MoT) Use of composition Defined dosing regimens Specific indicatio
Slide 33: Well-Capitalized with Funding from Leading Healthcare Investors
\ WELL-CAPITALIZED WITH FUNDING FROM LEADING HEALTHCARE INVESTORS OVERSUBSCRIBED $115M UPFRONT FINANCING LED BY INCLUDING MAY 2026 FINANCING
Slide 34: Anticipated Milestones
ANTICIPATED MILESTONES 1Q27 LAM-001 BOS Phase 2 Data 1Q28 LAM-001 PH-ILD Phase 2b Data 4Q28 LAM-001 SAPH Phase 2 Data
Slide 35: Thank You
flutyatx THANK YOU ecso OCTOBER 2026
IRulya Therapeutics — Investor Presentation (October 2026) on 6ix